More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$230389507
EPS
-4.63
P/E ratio
--
Price to sales
1.28
Dividend yield
--
Beta
0.735881
Previous close
$3.99
Today's open
$3.95
Day's range
$3.74 - $3.97
52 week range
$3.57 - $9.94
CEO
Mihael H. Polymeropoulos
Employees
533
Headquarters
Washington, DC
Exchange
NASDAQ Global Market
Shares outstanding
60469687
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
NEREUS™ - The Goat of Biscayne Bay Arrives for Miami Art Week
WASHINGTON, Nov. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that "NEREUS™ – The Goat of Biscayne Bay" is arriving during Miami Art Week, offering a floating activation on Biscayne Bay for people who experience motion sickness. The activation celebrates NEREUS™ (tradipitant), the first new prescription treatment for the prevention of motion-induced vomiting in more than 40 years.
PRNewsWire • Nov 11, 2026

Vanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences
WASHINGTON, Nov. 3, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in November 2026: The 8th Annual Wolfe Research Healthcare Conference in New York City on Tuesday, November 10, 2026. The Stifel 2026 Healthcare Conference in New York City on Wednesday, November 11, 2026.
PRNewsWire • Nov 3, 2026

Vanda Pharmaceuticals Inc. (VNDA) Q3 2026 Earnings Call Transcript
Vanda Pharmaceuticals Inc. (VNDA) Q3 2026 Earnings Call Transcript
Seeking Alpha • Oct 29, 2026

Vanda Pharmaceuticals Q3 Earnings Call Highlights
Vanda Pharmaceuticals NASDAQ: VNDA reported third-quarter revenue growth of 24% from a year earlier, supported by higher Fanapt sales and a sharp sequential increase in HETLIOZ revenue tied partly to specialty-pharmacy purchasing and shipment timing. The company also said operating expenses declined 18% from the second quarter as certain late-stage development and launch-preparation activities concluded.
MarketBeat • Oct 29, 2026

Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results
Q3 2026 Total Revenues increased 24% to $69.8 million compared to Q3 2025 and 38% compared to Q2 2026 Q3 2026 Total Operating Expenses decreased by 18% to $93.3 million compared to Q2 2026 Announced positive results from the Phase III study of NEREUS™ for prevention of GLP-1-induced vomiting NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 BYSANTI™ commercial launch expected in Q4 2026 Quimilza™ BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026 WASHINGTON, Oct. 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2026. "We are pleased with the strong revenue growth in the third quarter, increasing 24% year-over-year, driven by continued Fanapt momentum and the early contribution from our NEREUS commercial launch, while operating expenses decreased 18% compared to the second quarter as key Phase III and launch-preparation activities conclude," said Mihael H.
PRNewsWire • Oct 28, 2026

Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.38 per share a year ago.
Zacks Investment Research • Oct 28, 2026

Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released results from its Phase 3 trial evaluating Nereus, an oral therapy aimed at preventing vomiting associated with GLP-1 receptor agonist treatments.
Benzinga • Oct 27, 2026

Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting
NEREUS™ significantly reduced semaglutide induced vomiting including frequent multi-day and extreme vomiting Key Results Any vomiting (primary) 43.0% (61/142) vs 58.5% (96/164) placebo (p=0.006); 27% relative reduction Vomiting + severe nausea (key secondary): 33.1% (47/142) vs 50.6% (83/164) (p=0.002); 35% relative reduction Frequent multi-day vomiting (>2 episodes on more than one day): 6.3% (9/142) vs 15.9% (26/164) (p=0.008); 60% relative reduction Extreme vomiting (>10 total episodes): 2.8% (4/142) vs 14.6% (24/164) (p=0.0003); 81% relative reduction WASHINGTON, Oct. 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced positive results from Study 3601 (VP-VLY-686-3601), a Phase III randomized, placebo-controlled study evaluating NEREUS™ (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting associated with GLP-1 receptor agonist therapy. The study showed significant reduction in overall vomiting episodes (27% p=0.006 as well as reduction of frequent (60% p=0.008) and extreme vomiting (81% p=0.0003) episodes.
PRNewsWire • Oct 27, 2026

Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
Conference Call and Webcast to Follow WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2026 on Wednesday, October 28, 2026, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, October 28, 2026, during which management will discuss the third quarter 2026 financial results and other corporate activities.
PRNewsWire • Oct 21, 2026

Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Wednesday shared an update regarding its clinical development pipeline.
Benzinga • Oct 15, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Vanda Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.